Oculus Innovative Sciences talks upcoming IPO at $12-$14 per share

By Jennifer Chiou

New York, Nov. 13 - Oculus Innovative Sciences, Inc. set price talk for its upcoming initial public offering at between $12.00 and $14.00 per share in an S-1/A registration with the Securities and Exchange Commission.

On July 3, the company filed for an estimated $80.5 million IPO.

A.G. Edwards and Jefferies & Co. are joint bookrunners and First Albany Capital and C.E. Unterberg, Towbin are co-managers.

The Petaluma, Calif.-based company develops and markets products for the prevention and elimination of infection in chronic and acute wounds.

Its platform technology, Microcyn, is a non-toxic, super-oxidized water-based solution that is designed to eliminate a wide range of pathogens including viruses, fungi, spores and antibiotic resistant strains of bacteria.

IPO proceeds will be used to expand sales and marketing, fund clinical trials and research as well as general corporate purposes.

Oculus Innovative Sciences said it had a $2.318 million operating loss on revenues of $2.584 million for 2006 ended March 31, compared with an operating loss of $2.166 million on revenues of $1.356 million for the same period in 2004.

Currently Hojabr Alimi is the largest shareholder with 34% of the equity followed by Akihisa Akao at 12.8% and Robert Miller at 4.6%.

The company has applied to list its stock on the Nasdaq National Market under the symbol "OCLS."

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.